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Chapter I: Introduction 
 
A. Background 
The goal of evidence based dentistry, which can be applied to the specialized field of orthodontics, 
is to allow the clinician to deliver the most effective, efficient, and predictable treatment [1]. 
Evidence based dentistry includes three fundamental components, two of which are in the hands 
of the orthodontist: scientific evidence and clinical expertise [2]. The final component incorporates 
the patients’ needs and preferences; patient preferences regarding orthodontic treatment often 
hinge around the treatment duration [3]. According to the most recently published systematic 
review, comprehensive orthodontic treatment, on average, requires less than two years to complete 
[4]. However, in some cases, treatment time is increased from this two year average duration. 
Factors, such as extraction therapy, earlier initiation of treatment for specific malocclusions, non-
compliance, initial severity of the malocclusion, and impacted canines appear to be associated with 
increased treatment time [5].  
 
Increased orthodontic treatment time can result in a multitude of damaging effects to the oral cavity 
such as: white spot lesions [6] [7], dental caries [7], root resorption [8], and gingival inflammation 
[9]. Increased time in orthodontic appliances can also lead to the decline of patients’ compliance 
[4], which can impact the quality of the orthodontic finish. Therefore, the ability to decrease 
treatment time would be advantageous to both patients and orthodontists alike. In a recent 






patients wished that orthodontic treatment lasted 18 months or less [3]; this would be a 25% 
reduction in the overall treatment duration than the most currently reported average [5].  
 
There exist many modalities to accelerate the rate of tooth movement, which has spawned the 
development of a variety of products marketed by the orthodontic industry and advertised to 
decrease treatment time. However, about half of the marketed orthodontic products are 
investigated after their introduction, with many of the analyses not confirming the purported 
effectiveness of the intervention [10].  Historically, attempts to find a modality to enhance the rate 
of tooth movement, in order to decrease overall time in orthodontic appliances, have focused on 
three main approaches: 1. Pharmacological, 2. Surgical, and 3. Mechanical.  
 
Published investigations have previously examined the effects of local or systemic 
pharmacological administration of factors such as parathyroid hormone (PTH) [11], vitamin D3 
[12], prostaglandins [13], and thyroxin [14]. While these biological factors have been found to 
increase the rate of tooth movement, they have also shown adverse effects, such as root resorption 
[15] [16], drug-induced side effects, for those agents delivered systemically [17], or pain when 
injected locally [18].  
 
Surgical procedures such as corticotomy [19] [20] [21], corticision [22] , and piezocision [23] have 
also been cited as techniques to increase the rate of orthodontic tooth movement. Some proponents 
of these surgical techniques suggest that this increased rate of tooth movement is due the Regional 






bone turnover and decrease in bone density after injury [19] [24]. However, a multitude of studies 
have shown the short-term, 2-3-month average effect of the RAP, which decreases the significance 
of its utilization [19]. In addition, due to the invasive nature of the surgical methods, patients are 
less inclined to consent to these adjunctive treatments [3] [25].  
 
Lastly, the use of mechanical vibration to the dentition has also been hypothesized to increase the 
rate of tooth movement by stimulating bone remodeling through exogenous piezoelectricity [26]. 
The use of adjunctive vibration therapy could be well-accepted by patients due to its non-invasive 
nature without any adverse systemic effects. In fact, Uribe et al. found that adult patients, 
adolescent patients, and their parents were 78%, 87%, and 70% neutral or willing to use a vibrating 
device, respectively [3]. However, although these intraoral vibrating devices already exist on the 
market and are utilized in many practices by many patients, it is still unknown if they do, in fact, 
decrease overall treatment time.   
 
1. Vibration and Orthodontic Tooth Movement 
The use of an external vibrational force as a supplemental appliance in combination with 
orthodontic treatment was first proposed in a 1982 patent by Craven Kurz in which he described a 
vibrating headgear/mouthpiece device [27]. Animal studies examining the effect of vibration have 
exhibited the potential for an acceleration of tooth movement by triggering the inflammatory 
process through alteration of the periodontal apparatus or by increasing levels of pro-inflammatory 
cytokines, such as Receptor Activator of Nuclear Factor Kappa-B Ligand (RANK), an osteoclast 






mechanical vibration with low-magnitude and high frequency can enhance bone remodeling, 
prevent bone loss, and improve bone healing in animals and humans [31] [32] [33] [34]. However, 
contrary to the possible mechanisms underlying the acceleratory effects, the process by which 
these appositional effects occur, is not clearly understood.  
 
Following three landmark papers by Mao et al., which showed the potential for vibrational forces 
to increase cranial suture width and bone formation [35] [36] [37], a venture to deliver vibrational 
therapy to humans was achieved; a novel device, called AcceledentÒ, which applies a cyclic force 
of 25g at a frequency of 30 Hz was developed in 2009. However, the AcceledentÒ device is a prime 
example of the objective behind the meta-epidemiological investigation by Seehra et al. [10]: this 
device was marketed and adopted by the orthodontic community before its clinical use was 
verified. In a case report which included 14 patients who used the novel AcceledentÒ device, Kau 
et al. reported a monthly rate of tooth movement of 2.1mm and 3.0mm in the mandibular and the 
maxillary arches, respectively. Although there were no control patients used for comparison, Kau 
et al. concluded that this rate of tooth movement was significantly faster than the usual 1 mm of 
tooth movement per month previously reported in the literature [38]. A randomized clinical trial 
was then performed by Pavlin et al., assessing the rate of space closure during canine retraction 
with supplemental vibration provided by the AcceledentÒ device. The results showed an average 
rate of tooth movement of 1.16 mm/month when the AcceledentÒ appliance was used for 20 
minutes/day, corresponding to an increase of 48% in the rate of space closure [39]. Another 
randomized clinical trial was performed by Miles et al., using a slightly different vibration device 






than the AcceledentÒ device. They investigated the effect of vibration on lower incisor alignment 
as measured by the Little’s Irregularity Index, and concluded that there was no statistically 
significant difference between the rate of tooth movement between the control and experimental 
groups [40]. Using a similar protocol, Bowman et al. found an increased rate of leveling and 
aligning during comprehensive treatment by 30% and 29-40%, respectively; however, this 
research was retrospective in nature, leading to some inherent bias [41].   
 
A systematic review was published in the Cochrane Library in 2015, which included two of the 
aforementioned studies: Miles et al. (2014) and Pavlin et al. (2015). The Cochrane Review 
concluded that all of the available evidence was of very low quality. Therefore, it was not possible 
to determine if there is a positive effect of using a vibration device in conjunction with fixed 
appliances to accelerate tooth movement [42].  
 
Since the systematic review in 2015, several high-quality prospective, randomized clinical trials 
have been published. Woodhouse et al. conducted a prospective randomized clinical trial which 
found no evidence that supplemental vibration added to regular orthodontic treatment increases 
the rate of initial alignment or reduces the amount of time required to achieve final alignment [43]. 
Miles et al. published two randomized clinical trials comparing the effects of the AcceledentÒ 
device on the rate of tooth movement with lower incisor irregularity and space closure during 
canine retraction, in 2016 and 2018, respectively. Neither paper found an effect of vibration on the 
rate of incisor alignment [44] or the rate of space closure [45]. Furthermore, in the 2018 






compliers (daily usage of the AcceledentÒ device > 75%) versus control subjects; the effect of 
vibration on the rate of space closure was still not significant [45]. Lastly, a multi-center, 3-arm 
parallel randomized clinical trial undertaken by DiBiase and colleagues in England was published 
recently. They assessed the effect of AcceledentÒ on the rate of mandibular space closure (canine 
retraction) and overall treatment duration; however, they did not find any significant differences 
between the subjects in the control group and the subjects in the AcceledentÒ group [46]. While 
the most recent, well-conducted research suggests that there is no advantage to the application of 
cyclical forces on the rate of tooth movement [43] [44] [45] [46], there is still a need for additional 
well-designed clinical trials.   
 
2. Vibration Treatment- Pain and Quality of Life During Orthodontic Treatment 
In addition to the advertised enhanced effects on the rate of tooth movement, the AcceledentÒ 
device has been marketed as an adjunctive method to reduce the amount of dental pain that 
orthodontic patients experience during active treatment. Four randomized clinical trials with 
contradictory results have been published regarding this effect: one study concluded that pain was 
decreased when a vibration appliance was used [47], while the other three studies found no 
statistically significant differences between patients using a vibration device and a control group 
[40] [44] [48]. The study by Woodhouse et al. included a novel sham device group into the study 
design. However, even with the sham device group, which might uncover a placebo effect, there 
was no significant differences found in pain levels during the week following the placement of 
fixed appliances and wire insertion between the three groups [48]. Lastly, in the randomized 






using the Visual Analog Scale. They found no significant differences in reported pain levels at any 
timepoint between subjects using the AcceledentÒ device and control subjects [44].  
 
According to published research, the presence of a malocclusion is associated with a low Oral 
Health Quality of Life (OHQoL) [49]. Irrespective of this information, the literature does not 
support any conclusive evidence on the psychosocial effect of orthodontic treatment. In studies 
performed on Brazilian populations, both adult and adolescent patients who received orthodontic 
treatment were found to have a significantly higher OHQoL after treatment is completed than 
untreated subjects [49] [50]. However, follow-up research has shown that some patients go through 
a transitional phase of deterioration of the OHQoL during the active orthodontic phase, possibly 
due to pain, gingivitis, ulceration, and speech problems [51] [52]. Due to a dearth of literature 
investigating the effects of orthodontic treatment on OHQoL, future research should be undertaken 
to assess not only the psychosocial impact, but also other factors that could possibly contribute to 
the improvement of the overall orthodontic experience.  
 
3. Vibration Treatment- Bone Remodeling Biomarker Measurements 
Orthodontic tooth movement occurs subsequent to the initiation of the inflammatory process by 
remodeling of the periodontal ligament (PDL) and alveolar bone [53]. While vibrational loading 
has been claimed to stimulate bone remodeling [26], and thus tooth movement, the underlying 
biological mechanisms are not clearly understood. An important marker to illustrate the rate of 
bone turnover is Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), a molecular 






and survival of osteoclasts. The binding of RANKL with RANK (which is expressed at the surface 
of the osteoclast) induces the differentiation of the immature osteoclasts into functional cells which 
can resorb bone. On the other hand, osteoprotegerin (OPG), also produced by the osteoblasts, acts 
as a soluble receptor for RANKL. This inhibits the final stages of the osteoclast differentiation, 
thereby serving as a negative feedback system for the maintenance of equally balanced bone 
formation and resorption [53]. The role of the OPG/RANKL system in bone remodeling has been 
illustrated in several studies performed on animals [54] [55] [56] and recently on humans during 
orthodontic treatment [57] [58].  
 
Matrix metalloproteinases (MMPs), a family of endopeptidases that play a key role in collagen 
breakdown, tissue remodeling and degradation of the extracellular matrix, serve as important 
biomarkers of bone remodeling in conjunction with orthodontic tooth movement [53]. Multiple 
studies have shown increased expression of certain metalloproteinases during orthodontic 
treatment: increased levels of MMP-9 were found in the gingival crevicular fluid in response to 
external pressure on teeth [59] [60] [61] [62] [63]. MMP-13 was also expressed in the PDL and 
alveolar bone soon after the application of an orthodontic force [62] [64] [65]. Increased levels of 
MMP-3 and MMP-8 have also been found after orthodontic tooth movement in both animal and 
human models [62] [65] [66] [67].  
 
Lastly, Tumor Necrosis Factor alpha (TNF-α) and interleukins are cytokines which increase with 
orthodontic force application in rats [68] and humans [59] [69] and are involved in the induction 






and IL-17 [73] are specific regulators in the bone remodeling process and therefore, are present in 
higher concentrations during orthodontic tooth movement.  
 
To date, there is only one clinical study measuring the effect of vibration on bone metabolism 
biomarkers (IL-1β) during orthodontic tooth movement. Leethanakul et al. published their findings 
in 2016. They employed a split-mouth study design and a small sample-size of 15 subjects. The 
vibratory stimulus was provided by an electric Colgate Multi-Action toothbrush, rather than the 
AcceledentÒ device. Subjects were asked to apply the electric toothbrush for 5 minutes, 3x/day to 
one of their canine teeth being retracted for the duration of the 3-month study. Levels of IL-1β 
were measured in the gingival crevicular fluid (GCF) at four timepoints, 2 weeks apart. They found 
that after 2 months, the levels of IL-1β were higher on the pressure sides of the experimental 
canines, which was associated with an increased rate of tooth movement [74]. However, while 
these results are interesting, they should be interpreted with caution; due to the nature of the 
toothbrush as the vibratory agent, the force cannot be calibrated between patients. In addition, the 
sample size was small.   
 
Similar to the conclusions of Leethanakul et al., the expression of various pro-inflammatory 
biomarkers of bone remodeling in subjects utilizing vibration in conjunction with orthodontic 
treatment could elucidate the specific pathways that are activated when tooth movement 
acceleration occurs. The test chosen to conduct this assessment must have an acute sensitivity to 
the factors of interest, as well as be minimally invasive to allow for good acceptance from patients. 
Multiple methods to assess biological factors have been published in the literature including: 






analysis in the oral health field. It has been proposed that saliva mirrors the body’s overall health, 
a statement which qualifies its prospective use as diagnostic tool. Saliva has many advantages such 
as its non-invasive nature, its ease of use, and the fact that sufficient quantities can be easily 
obtained for analysis [75]. Saliva has previously been used to predict the risk of caries and 
periodontitis, as well as the diagnosis of oral cancer, breast cancer, salivary gland disease, hepatitis, 
HIV and HCV [76]. Within the field of dentistry, only a few studies have used saliva to evaluate 
the expression of bone remodeling factors [77] [78]; however, this emerging field shows great 
promise for future diagnostics.  
 
B. Study Rationale 
Orthodontic treatment duration averages around 24 months [4] . There are several advantages for 
reduced treatment time: decreased risk of root resorption [8] and decalcification [6] [7], less time 
for maintenance of periodontal health [9], and a decreased chance of patient non-compliance from 
prolonged treatment [4], which can impact orthodontic outcomes. AcceledentÒ advertises the 
proposed benefits of decreased treatment time and decreased pain when using their device, and we 
aim to investigate if these claims are supported by a high-quality investigation.  
 
Clinical studies which investigate the use of a vibration device in conjunction with fixed appliances 
have assessed the acceleration of tooth movement, either during the alignment or space closure 
phase, and the amount of experienced pain. These studies have produced a range of conclusions, 
which has sourced the controversy within this field of tooth movement acceleration [39] [40] [43] 






review published in the Cochrane Journal does not include the four most recent randomized 
clinical trials, it stipulated a very low level of evidence among the included articles [42]. Therefore, 
there is a clear need for more well-designed controlled studies in order to elucidate the clinical 
effects of the application of vibration on orthodontic tooth movement.    
 
Lastly, the biological mechanism underlying the acceleration of the rate of tooth movement is 
unknown. The identification of specific biomarkers in the saliva that are stimulated by 
supplemental vibration could help our orthodontic profession to understand the pathways involved 
in accelerated bone remodeling. In the future, this could lead to treatment which would target 
specific acceleratory biomarkers with the objective to reduce orthodontic treatment time. The aim 
of this study is to identify novel biological factors which are expressed in subjects undergoing 
orthodontic tooth movement in conjunction with vibration provided by the AcceledentÒ device.  
 
C. Outcome Assessment 
Primary outcomes: Changes in the expression of salivary biomarkers of bone remodeling  
Secondary outcomes:  
o Changes in the rate of alignment of lower anterior teeth (canine to canine) 
o Changes in tooth mobility 
o Changes in pain and Oral Health and Quality of Life 








Chapter II: Hypotheses, Objectives, and Aims 
 
A. Hypotheses and General Objectives 
1. Null Hypotheses 
1. There is no difference in the expression of biological markers of bone remodeling between 
combined vibration-fixed appliance treatment and fixed appliance treatment alone. 
 
2. There is no difference in the degree of tooth mobility in patients undergoing combined 
vibration-fixed appliance treatment compared to fixed appliance treatment alone. 
 
3. There is no difference in the rate of lower incisor alignment in patients undergoing combined 
vibration-fixed appliance treatment compared to fixed appliance treatment alone during the first 
3 months of treatment. 
 
4. There is no difference in the reported pain or reported oral health quality of life in patients 
undergoing combined vibration-fixed appliance treatment and fixed appliance treatment alone.  
 
2. General Objectives 
There is a clear lack of evidence in the orthodontic literature about the effects of a vibration device 
on the rate of tooth movement, pain, and oral health quality of life. Additionally, the biological 






primary objective of this study is to assess the potential influences of a vibration device on the 
expression of biomarkers of bone remodeling.  
 
B. Specific Aims and Objectives  
1. To determine if supplemental vibration in addition to fixed orthodontic appliance treatment can 
alter the expression of biological factors involved in bone remodeling during orthodontic tooth 
movement. 
 
2. To further elucidate the role of supplemental vibration on the degree of tooth mobility during 
fixed orthodontic appliance treatment.  
 
3. To determine if supplemental vibration in addition to fixed orthodontic appliance treatment 
increases the rate of orthodontic tooth movement during the alignment phase of treatment.  
 
4. To evaluate the effect of supplemental vibration on experienced pain and on the oral health 
quality of life in subjects undergoing orthodontic treatment.  
 
Chapter III: Materials and Methods 
 
A. Study Design and Screening Procedures  






This study was approved by the Institutional Review Board (IRB) of University of Connecticut 
(IRB #14-117-2). The aim of this study was to perform a randomized clinical trial recruiting a total 
of 40 patients randomly divided in four groups: (1) 10 male subjects randomized to the control 
group; (2) 10 male subjects randomized to the vibration group; (3) 10 female subjects randomized 
to the control group; (4) 10 male subjects randomized to the vibration group. The randomization 
of subjects is diagrammed in the chart below:   
 
 
No randomized clinical trials are currently available to predict the effects of vibration with the 
AcceledentÒ device on the expression of pro-inflammatory biomarkers. Therefore, this study 
serves as a pilot study consisting of 40 subjects randomized into 4 groups divided by gender and 
























2. Screening & Recruitment Procedures 
Prospective subjects were screened for potential inclusion in this study during the regular screening 
procedures followed for all new patients who present to the orthodontic clinic at UCONN Health. 
The orthodontic provider assigned to the patient at the screening appointment determined if the 
patient was likely to qualify according to the inclusion/exclusion criteria for participation in the 
trial and advised the study coordinators (MCC/SR) if the clinical indicators were met. The initial 
eligibility requirements included any healthy male or female patient between the age of 15-35 
years old, non-smoker, not prescribed any medications, with good oral hygiene, a minimum of 
5mm of lower anterior crowding (canine to canine), and a non-extraction treatment plan. If the 
prospective subjects met the initial criteria, the study coordinator then confirmed the possible 
eligibility by consulting the screening forms, models, and/or radiographs. In the situation where 
the patient was between the age of 15.0-17.11 years old, the patient’s provider asked the patient’s 
parent for permission to provide the clinical information to the study coordinator.   
 
3. Enrollment 
After the patient’s primary provider determined their patient’s potential inclusion into the trial and 
verified that their patient was interested in becoming a subject, the study coordinator met with the 
patient at their next appointment. The study was then explained to the patient in detail and informed 
consent was obtained by the patient him/herself and/or the patient’s parent (in the situation where 
the subject was under 18 years old). Potential subjects had to satisfy the following 







Inclusion Criteria Exclusion Criteria 
Healthy, non-smoker with no systemic medical 
conditions and taking no routine medications Patients requiring extractions as part of their treatment plan  
15 to 35 years of age at the time of bonding (T0) Smoking or excessive alcohol consumption 
Non-extraction treatment plan or no extractions 
required during the first 6 months of treatment Patients with edentulous areas (missing teeth) 
At least 5mm of crowding in the mandibular arch Evidence of periodontal disease (any pocket depths >4mm)                         
Full-complement dentition: 1st molar to 1st molar  Use of anti-inflammatory drugs within 2 days of bonding 
Good oral hygiene Uncontrolled diabetes 
 Dentofacial deformities (cleft palate, hemifacial microsomia, etc.) 
 
Subjects routinely taking any of the following medications: 
+ Corticosteroids (including for asthma) 
+ Bisphosphonates 
+ Anti-inflammatory drugs such as Ibuprofen 
+ Nicotine Patch 
+ Estrogen 
+ Opioids 
+ Growth Hormone 
+ Relaxin 
+ Anti-coagulants 
+ Stimulants (ADHD) 
 
Diseases that could affect bone metabolism: 
+ Parathyroid or thyroid dysfunction 
+ Osteoporosis or Osteomalacia 
+ Vitamin D deficiency 
+ Fibrous dysplasia 
+ Paget’s disease 
+ Multiple Myeloma 
+ Osteogenesis Imperfecta 
+ History of Bone Metastasis 
 
 
B. Study Procedures 
1. Standardized Orthodontic Treatment Protocol 
The patients enrolled in this clinical trial had to follow a standardized protocol in order to minimize 
any potential variability in treatment that could confound the trial outcomes. All subjects were 
bonded with passive self-ligating brackets (CarriereÒ) featuring a 0.022” x 0.025” slot and MBT 
prescription from lower right second premolar to lower left second premolar, as well as a bonded 
tube on the first molars. At the bonding appointment (T0), a 0.014” Cu-NiTi wire was engaged 
into the mandibular arch brackets and was maintained through the T2 appointment. Before the 






to verify that there was no permanent deformation that could confound the potential for lower 
incisor alignment. At T2, the lower archwire was switched to a 0.014” x 0.025” Cu-NiTi wire. 
After initial bonding (T0), all subjects returned for trial timepoints T1, T2, T3 in conjunction with 
their regular orthodontic adjustments with their orthodontic provider every 4-6 weeks.  
 
If a bracket debonded between adjustment appointments, the subject had 7 days to advise his/her 
provider and report to the clinic to have the bracket rebonded again to the ideal position. In 
addition, the subjects were instructed not to take any anti-inflammatory medications during the 
course of the trial and to abstain from eating or drinking for one hour prior to their next four 
appointments (T0, T1, T2, T3 timepoints). Failure to follow this protocol led to immediate 
disqualification from the study.   
 
2. Randomization Procedure 
Block randomization was utilized for randomization of subjects included in this trial. Since trial 
groups were subdivided by gender, separate randomization into the AcceledentÒ  or control group 
was performed separately for male and female subjects. 40 opaque envelops with allocation group 
assignments inside (10 AcceledentÒ / 10 control) were assembled for each group (20 male and 20 
female subjects). During the bonding appointment (T0), the subject was asked to pick an envelope 
and disclose their allocated group. For trial subjects randomized into the AcceledentÒ group, 
instructions on how to operate the AcceledentÒ device were specified by the study coordinator 






throughout the entirety of the study duration (approximately 3 months) according the to 
manufacturer’s instructions, which were included with the device.  
 
3. Data Collection Procedure 
At the bonding appointment (T0), baseline measurements of the following data were recorded 
and/or collected: (1) unstimulated whole saliva, (2) Periotest measurements, (3) an alginate 
impression of the mandibular arch, and (4) Oral Health Quality of Life questionnaire. The 
aforementioned four measurements were collected/recorded again at the T1 timepoint (5-6 weeks 
later), T2 timepoint (10-12 weeks later), and T3 timepoint (15-18 weeks later). Each subject was 
scheduled at approximately the same time of the day in order to minimize any differences in 
salivary biomarker levels due to circadian rhythms.  In addition, subjects were given a Pain Diary 
to fill out for the first 7 days following their T0, T1, and T2 appointments. Subjects were instructed 
to return the Pain Diary at the following appointment.   
 
o Saliva Collection and Analysis 
Collection of unstimulated whole saliva was performed following the protocol described by 
Navazesh and Kumar [79]. The saliva was collected into a sterile tube at T0, T1, T2, and T3 by 
passive drooling for either 15 minutes or until 10 mL was reached. Protease inhibitor was then 
added to the saliva in a ratio of 150ul protease inhibitor/10mL saliva and then centrifuged at 4000 
rpm for 30 minutes at 4º Celsius, in order to remove cellular debris. Throughout the saliva 






biomarkers. The samples were stored in a -80º Celsius freezer until biomarker analysis was 
ultimately performed.   
 
Salivary biomarkers were assessed with Multiplex assay. Seventeen biomarkers were analyzed 
with the Multiplex analysis: OPN (osteopontin), RANKL, SOST (sclerostin), OPG, MMP1, 
MMP8, MMP9, MMP13, TNF-α, IL-1β, IL-3, IL-6, IL-8, IL-11, IL-18, and DKK1. Protein assay 
of all saliva samples was completed and the samples were diluted to equal protein concentrations 
before Multiplex assay was initiated. Multiplex panels were supplied by R&D Systems, Inc and 
were ran by the Core Laboratory at UCONN Health.  
 
o Cast Analysis 
Dental casts were assessed by one blinded evaluator (DFL) to determine the rate of tooth 
movement. Each mandibular model was evaluated for the mandibular anterior alignment from 
canine to canine, using Little’s Irregularity Index. This index uses the displacement of the adjacent 
anatomic contact points of the mandibular incisors (from the mesial of the right canine to the mesial 
of the left canine) in millimeters and determines the total Irregularity Index of the subject by adding 
the five measurements together [80]. The measurements were recorded for all 40 subjects at all 
four study timepoints: T0, T1, T2 and T3 with a digital caliper (Neiko Tools USA) held parallel to 
the occlusal plane. The blinded evaluator recorded two Irregularity Index measurements for each 
cast, taken one week apart and these two recorded measurements were averaged to produce the 
Little’s Irregularity Index value per subject. Figure 1 illustrates how Little’s Irregularity Index is 






o Periotest Measurements 
The mobility of specific teeth in the mandibular arch (central incisors, canines, and second 
premolars) was assessed with the Periotest (Siemens AG, Bensheim, Germany) device as 
previously described by Liou et al. [82]. The lower wire was removed and the tip of the device 
was held parallel to the floor, perpendicular to the tooth axis, and 2 mm away from the labial 
surface. Before taking Periotest measurements, the study coordinator located an area on the labial 
surface of the tooth which had sufficient space for the tip of the Periotest to contact the surface in 
order to obtain consistent measurements. Each tooth was measured 3 times and the average 
measurement was then calculated. The value obtained by the Periotest can range from -8.0 to +50.0 
and the unit of measure is Periotest Value or PTV [83]. The scale correlates with Miller’s Index as 
shown in Table 1. 
 
o Orthodontic Pain Assessment  
Subjects were instructed to record their subjective pain on a Pain Diary for the first seven days 
including and following their T0, T1, and T2 appointments. Experienced pain was assessed using 
the Visual Analog Scale (VAS). Subjects were asked to place a tick mark on the 10mm line 
correlating with their experienced pain ranging from 0 (no pain) to 10 (extreme pain). The 
completed diary was returned at the next appointment. The VAS for each subject at each trial 
timepoint was recorded by measuring the location of the tick mark on the 10mm line and 
converting this into an equivalent Visual Analog Score (1mm: VAS = 10). The Pain Diary supplied 







o Oral Health Quality of Life (OHQoL) 
Subjects were asked to complete an Oral Health Impact Profile (OHIP-14) questionnaire at their 
T0, T1, T2, and T3 appointments in order to measure their perception of the impact of their oral 
conditions, as well as the possible impact of using a vibration device on their well-being. The 
questionnaire includes 14 questions divided into specific categories including functional 
limitation, physical pain, psychological discomfort, physical disability, social disability, and 
handicap. Each question is answered based on a 5-point scale correlated with frequency, with 
scores that range from 0 (never) to 4 (very often). The recorded score (0-4) is then multiplied by 
the attributed weight. The 14 values (score x weight) are summed together to produce a total 
OHQoL value [84]. The OHQoL table with dimensions, questions, and their weights can be found 
in Table 2.   
 
o AcceledentÒ Device Usage Compliance  
Average daily usage of the AcceledentÒ device was recorded for those subjects allocated to the 
AcceledentÒ group over the trial duration (T0-T3). The AcceledentÒ  device contains a timer which 
stores usage data, which can be downloaded in Excel format and saved. Subjects in the 
AcceledentÒ group were instructed to bring their vibration device with them at their T1, T2, and 
T3 appointments, allegedly to check its function. Usage data was downloaded and saved to the 
subject’s trial record. Average daily use was calculated between trial timepoints (T0-T1, T1-T2, 







Some subjects did not use the AcceledentÒ device (average daily usage = 0 minutes) for multiple 
days in a row leading up to the final trial timepoint (T3). A flaw of the AcceledentÒ timer is that 
usage data is not recorded on the device when this situation occurs. Therefore, using the dates 
between trial timepoints, days in which usage data was missing (because the subject did not use 
the device) was calculated manually by recording the average daily usage as 0 minutes/day.  
 
C. Statistics  
The Mann-Whitney Test was used to assess differences between the AcceledentÒ and control 
groups for all continuous variables: Periotest measurements, changes in Little’s Irregularity Index, 
salivary biomarker concentrations, Visual Analog Scale scores, and Oral Health Quality of Life 
scores with α=0.05. 
 
Regression analysis was used to assess the effects of age, gender, and treatment group allocation 
on the outcome variables of rate of alignment and the concentrations of salivary biomarkers of 
bone remodeling. Significance was set at α=0.05.  
 
Pearson’s correlation coefficient with α=0.001 was used to analyze possible correlations between 
the salivary biomarker concentration, the change in the irregularity index, and the compliance with 









Chapter IV: Results 
 
Forty patients were ultimately enrolled; of these, 20 (10 males and 10 females) were allocated to 
the AcceledentÒ group and 20 (10 males and 10 females) were assigned to the control group. Trial 
enrollment was initiated in June 2014 and was concluded in December 2017. Out of the 40 subjects 
recruited, 3 subjects allocated to the control group were disqualified after enrollment. 1 female 
subject decided to continue her orthodontic treatment in another clinic, 1 male patient failed to 
present to his third appointment, and 1 female patient had an emergency medical procedure which 
required the administration of an anti-inflammatory drug. All 40 enrolled subjects were included 
in the final Intention to Treat (ITT) analysis, which is the recommended method in superiority 
trials to avoid any bias [85]. See the CONSORT flow diagram in Figure 3 for the progress of 
subjects through the phases of the trial.  
 
The mean age of female subjects was 22.0 years and the mean age of male subjects was 18.7 years 
at the start of treatment (T0). The mean age of subjects allocated to the AcceledentÒ and control 
group at the beginning of the trial (T0) was 21.1 and 19.7 years old, respectively.  
 
In regard to subjects’ compliance with the AcceledentÒ device, a wide range was observed. Based 
on the data recorded by the device, usage ranged from 0% to 104%, with a mean compliance rate 
of 53% (10.6 minutes/day) over the 3-month duration of the trial (T0-T3). When grouped by 
gender, female subjects had an average compliance rate of 66% and male subjects had an average 






each subject randomized into the AcceledentÒ group. When comparing compliance with the 
AcceledentÒ device over the course of the trial, no overall trend could be appreciated; some 
subjects stayed consistent with their compliance usage, others improved, while most subjects’ 
compliance decreased over the course of the trial (Figure 5).  
 
The initial irregularity means for the control group was 9.23mm (SD: 3.30mm) while the 
experimental group showed an average of 8.10mm (SD: 3.33mm), with no statistically significant 
difference between the groups (p=0.234).  Figure 6 shows the mean irregularity index at each trial 
timepoint for both groups. There was no statistically significant difference found between the 
experimental and control groups in terms of mean irregularity at each trial timepoint: T0, T1, T2, 
T3 (P =0.234, 0.140, 0.125, 0.293, respectively). For the changes in irregularity over the trial 
intervals, the data represented in Figure 7 shows that there were no significant differences in the 
rate of alignment between groups during any trial interval: T0-T1, T1-T2, T2-T3, T0-T3 (p = 
0.900, 0.643, 0.716, 0.713, respectively). Multivariate linear regression was completed to analyze 
any potential associations between the initial irregularity, age, sex, and type of intervention on the 
reduction of the irregularity index; however, no significant associations were found. Multivariate 
linear regression was also completed to analyze potential associations between compliance with 
the AcceledentÒ device and the change in Little’s Irregularity Index at different trial intervals; 
however, no significant association was found. This data is presented in Table 3.  
 
In terms of tooth mobility, as measured by the Periotest, there were no statistically significant 






premolar, lower right canine, lower right central incisor, lower left central incisor, lower left 
canine, lower left second premolar) at any time points: T0 (p=0.829, 0.516, 0.607, 0.105, 0.787, 
0.705, respectively), T1 (p=0.156, 0.779, 0.474, 0.866, 0.574, 0.888, respectively), T2 (p=0.090, 
0.953, 0.698, 0.372, 0.781, 0.895, respectively), or T3 (p=0.703, 0.976, 0.038, 0.361, 0.637, 0.410, 
respectively). See Figures 8, 9, 10, 11. 
 
The Visual Analog Scores (VAS) illustrated by the pain diary are represented in Figures 12-14. 
There were no significant differences in the level of pain intensity between AcceledentÒ and 
control subjects on any day (Day 1-Day 7) following trial timepoints T0: (p =0.974, 0.091, 0.987, 
0.508, 0.641, 0.507, 0.633, respectively) T1: (p=0.648, 0.351, 0.924, 0.632, 0.866, 0.614, 0.825, 
respectively) and T2: (p= 0.910, 0.940, 0.509, 0.393, 0.674, 0.858, 0.919, respectively).  
 
The evolution of Oral Health Quality of Life (OHQoL) during orthodontic treatment was assessed 
using the Oral Health Impact Profile-14 (Figure 15). The OHQoL scores were not statistically 
different between the AcceledentÒ and control subjects at any trial timepoints T0-T3 (p= 0.218, 
0.574, 0.548, 0.552, respectively).  
 
Temporal changes in the biomarker levels in the saliva were measured at each time points for all 
17 biomarkers: IL-1β, IL-3, IL-6, IL-8, IL-11, IL-18, RANKL, TGFβ1, TNF-α, SOST, OPN, OPG, 
MMP1, MMP8, MMP9, MMP13, and DKK1. The concentrations of all 17 biomarkers did not 
differ significantly between the AcceledentÒ and control subjects at any trial timepoint: T0-T3. 






groups at T0, T1, T2, T3, respectively: IL-1β (p=0.705, 0.855, 0.629, 0.464), IL-3 (p=0.924, 0.712, 
0.637, 0.902), IL-6 (p=0.607, 0.527, 0.770, 0.464), IL-8 (p=0.766, 0.249, 0.397, 0.976), IL-11 
(p=0.516, 0.517, 0.464, 0.389), IL-18 (p=0.977, 0.965, 0.951, 0.847), RANKL (p=0.745, 0.491, 
0.8772, 0.927), TGF-β1 (p=0.526, 0.765, 0.778, 0.695), TNF-α (p=0.323, 0.747, 0.619, 0.301), 
SOST (0.665, 0.500, 0.203, 0.259), OPN (p=0.182, 0.213, 0.617, 0.939), OPG (p=0.574, 0.254, 
0.658, 0.762), MMP1 (p=0.664, 0.661, 0.597, 0.290), MMP8 (p=0.570, 0.593, 0.953, 0.483), 
MMP9 (p=0.579, 0.399, 0.907, 0.577), MMP13 (p=0.542, 0.612, 0.750, 0.939), and DKK-1 
(p=0.848, 0.608, 0.965, 0.666). In addition, the ratio of RANKL/OPG concentration was analyzed 
at T0, T1, T2, and T3 (p=0.892, 0.164, 0.977, 0.445). Figures 16, 17, 18, 19 show the data for IL-
1β, OPG, RANKL, and TNF-α, respectively, as examples. Furthermore, no significant correlations 
were found between the rate of lower incisor alignment and the change of the concentration of 
salivary biomarkers of bone remodeling during any trial intervals or over the trial duration (T0-
T3). See Tables 4, 5, 6, 7.   
 
Chapter V: Discussion 
 
At the present time, clinical research has centered around three principal techniques in an attempt 
to increase the rate of tooth movement with the goal of decreasing the overall orthodontic treatment 
time. These include pharmacological, surgical, and mechanical approaches which, in their own 
specific way, attempt to modulate the underlying bone biology to increase the rate of tooth 
movement. The motivation behind this varied research is the fact that fixed appliance treatment, 






patients, such as white spot lesions [6] [7], caries [7], root resorption [8], and gingival 
inflammation [9].  
 
Regarding subjects’ compliance with the AcceledentÒ device, a wide range was observed in the 
percentage of its use, with a mean compliance rate of 53% (10.6 minutes/day) over the 3-month 
duration of the trial. This result is lower than the 67% compliance rate reported by Kau et al. [38] 
and the 79% compliance reported by Miles et al. [44]. This could be due to the fact that we 
discovered a flaw in the AcceledentÒ  timer. If subjects did not use the device for multiple days 
before the usage data was collected, these days were not recorded on the device. Therefore, in 
these situations, the actual daily usage had to be calculated manually, by inputting 0 minutes/day 
for these additional days. This flaw was not addressed in other studies, and could have possibly 
been overlooked, leading to an over-estimate of patient compliance with the device [38] [44].  
Some studies have investigated the effectiveness of the application of vibration in order to speed 
up orthodontic treatment, in relation to alignment in patients with crowding, or space closure, in 
patients undergoing an extraction treatment plan.  However, up to the present day, no consensus 
has been made. In our research, no statistically significant differences between groups were found 
neither in the mean incisor irregularity at each trial timepoint nor in the changes in irregularity 
over the 3 time intervals (T0-T1, T1-T2, T2-T3). These results are in agreement with other 
randomized clinical trials by Miles et al. [40] [44], Woodhouse et al. [43], and DiBiase et al. [46] 
which have all found in their respective studies, no increase in the rate of tooth movement (either 
alignment or space closure) when vibration was used in conjunction with fixed appliances. 






when the AcceledentÒ appliance was used for 20 minutes daily, which they stated corresponded to 
an increase of 48% in the rate of space closure compared to the control group. However, the 
interpretation of these results should be viewed with caution, since their study was considered to 
include low-quality evidence with a high risk of bias [42]. 
 
It is established that orthodontic tooth movement is a metabolic event featuring both bone 
resorption on the compression side and bone apposition on the tension side of the tooth movement. 
This alteration in the alveolar bone turnover is usually clinically associated with increased tooth 
mobility [18] [53]. To our knowledge, this is the first study assessing the amount of tooth mobility 
during orthodontic tooth movement and with supplemental vibration. In 2011, Liou et al. published 
an article in which they assessed the post-operative changes in bone metabolism after orthognathic 
surgery and the corresponding responses in the dento-alveolus, such as the changes in tooth 
mobility [82]. Throughout the post-operative evaluation (4-month duration), one of the main 
findings included an increase in tooth mobility between the first week after surgery and at the third 
month follow-up appointment. However, in our research, no statistically significant differences in 
the tooth mobility of lower premolars, canines, and central incisors were found between the control 
group and the AcceledentÒ group who applied a vibrational force daily, at any of the 4 trial 
timepoints (T0-T3). This makes clinical sense, as discussed previously, there was no difference in 
the change of lower incisor alignment between the two groups; if the rate of tooth movement is 
not significantly different, it would not be expected that tooth mobility would be significantly 







Previous studies have shown contradictory results of the pain levels in patients using a vibration 
device. Lobre et al. found that the level of pain was significantly reduced by using the AcceledentÒ 
device. They mentioned that using this device lowered the scores for overall pain and specifically 
biting pain during the 4-month duration of their study [47]. Our findings showed contradictory 
results to this study with no significant difference in the level of pain experienced by the subjects 
using the AcceledentÒ device. Woodhouse et al. in 2015 determined that the only significant 
predictor for mean pain was time. Their data also showed that the use of AcceledentÒ vibrational 
device did not have any significant effect on the pain level or analgesic consumption during the 
initial alignment phase [48]. In addition, our results are in agreement with Miles et al. who showed 
no significant differences between groups in regard to pain [40] [44].  
 
To follow, we did not find any significant differences in the Oral Heath and Quality of Life scores 
between the subjects in the AcceledentÒ and control groups. However, we did notice a trend that 
in both groups, scores increased at T1 and then decreased over the remainder of the trial. These 
findings are in agreement with previous research which showed that some patients go through a 
transitional phase of deterioration of the OHQoL during the first 4-6 weeks of orthodontic 
treatment [51] [52]. This result could possibly be explained by the hypothesis that, following the 
bonding appointment (T0), the patient can be self-conscious about the appearance of fixed 
appliances, experience pain, ulceration or speech problems, which would increase the overall score 
of the Oral Health Impact Profile (OHIP-14) questionnaire [51]. However, a prospective, 
controlled trial by Johal et al. described Oral Health Quality of Life scores returning to baseline 






that compares patients’ quality of life with the use of a vibration device during orthodontic 
treatment. Additional studies are needed to assess if there is any psychosocial impact from 
vibration therapy that could improve the overall quality of life for orthodontic patients during fixed 
appliance treatment.   
 
It has been successfully demonstrated that pro-inflammatory cytokines have an important role 
throughout the bone remodeling of the alveolus during orthodontic tooth movement by regulating 
the inflammatory process of bone resorption. There has been a recent interest in this particular 
research, both in rats and humans, in an attempt to elucidate the process of tooth movement. Rat 
and human research focusing on TNF-α [68] [69], IL-1β [59] [60] [69] [70] [86], IL-6 [70], IL-8 
[59] [70], MMP9 [59] [60] [62] [63], MMP8  [65] [66] [67], MMP13 [62] [64] [65], RANKL [29] 
[59] [86], OPN [86], and TNF-β1 [86] has found increased concentrations of these biomarkers 
after orthodontic force was applied. All of these pro-inflammatory biomarkers, as well as several 
others noted for their role in bone remodeling [18], were selected for our Multiplex assay analysis.  
 
On the clinical level, there has been only one study published by Leethanakul et al. in 2016. They 
found that at 6 weeks after the start of vibration stimuli and orthodontic tooth movement there 
were significant increases in the levels of IL-1β in the gingival crevicular fluid on the compression 
side of the teeth which received vibration stimuli from an electric toothbrush. They also found an 
increase in the rate of tooth movement (canine retraction) in the canines receiving vibratory stimuli 
as compared with control canines.  These clinically and biologically significant results differ from 






the trial duration between the control and AcceledentÒ groups, we found no statistically significant 
differences. In addition, an important marker to illustrate the rate of bone turnover is the 
RANKL/OPG ratio and multiple studies has clearly shown their rise during orthodontic tooth 
movement [57] [58]; however, we did not find any differences in this ratio between groups over 
the trial duration. When Pearson’s correlation analysis was completed, there were no significant 
correlations between the rate of lower incisor alignment and the change in pro-inflammatory 
biomarker concentrations for either AcceledentÒ or control groups. However, it is important to 
acknowledge that this difference in the analysis of saliva versus gingival crevicular fluid could 
affect biomarker detection, especially those which are expressed in lower concentrations in saliva. 
Our aim with collecting and analyzing saliva was to allow for a future diagnostic tool that is non-
invasive in nature, and for which sufficient quantities can be easily obtained for analysis.   
 
Chapter VI: Conclusions 
 
1. There was no difference in the expression of any of the analyzed biological markers of bone 
remodeling between the AcceledentÒ and the control groups over the trial duration and no 
association between the rate of alignment and compliance with the AcceledentÒ device.  
 
2. There was no difference in the degree of tooth mobility in subjects undergoing combined 







3. There was no difference in the rate of lower incisor alignment between subjects undergoing 
combined AcceledentÒ vibration-fixed appliance treatment and fixed appliance treatment alone 
over the 3-month trial interval and no correlation between the rate the lower incisor alignment 
and the change in concentration of the analyzed biomarkers of bone remodeling during trial 
intervals.  
 
4. There was no difference in the level of pain experienced in and no difference in the quality of 
life of subjects undergoing combined AcceledentÒ vibration-fixed appliance treatment 
compared to fixed appliance treatment alone.  
 
5. The average compliance usage of the AcceledentÒ device over the trial duration was 53%; 
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IRB #  _____________
Subject ID #_____________  Timepoint (circle):   T0    T1    T2                  
Biomarkers of orthodontic tooth movement with fixed appliances and vibration 
appliance therapy: A randomized clinical trial
PATIENT INSTRUCTIONS: Please place an “X” anywhere along the ruler which best describes 
your level of pain each day before dinner for the first week after your appointment. 
Day 1 (Day of you appointment)
Date: ___/___/_____ (DD/MM/YYYY) and Time: ________ PM
Day 2
Date: ___/___/_____ (DD/MM/YYYY) and Time: ________ PM
Day 3
Date: ___/___/_____ (DD/MM/YYYY) and Time: ________ PM
Day 4



















IRB APPROVAL DATE: 08/28/2017
IRB EXPIRATION DATE: 08/27/2018
IRB #  _____________
Subject ID #_____________  Timepoint (circle):   T0    T1    T2                  
Day 5
Date: ___/___/_____ (DD/MM/YYYY) and Time: ________ PM
Day 6
Date: ___/___/_____ (DD/MM/YYYY) and Time: ________ PM
Day 7















IRB APPROVAL DATE: 08/28/2017




















Assessed for eligibility (n= 45)
Excluded (n= 5)
¨ Not meeting inclusion criteria (n= 2)
¨ Declined to participate (n= 2)
¨ Other reasons (n= 1)
Analyzed (n= 20)
¨ Excluded from analysis (n= 0)
Lost to follow-up (patient relocation) (n=0)
Discontinued intervention (medication) (n=0)
Failed appointment (n=0)
Allocated to Experimental Group (n= 20)
¨ Received allocated intervention (n= 20)
¨ Did not receive allocated intervention (n= 0)
Lost to follow-up (patient relocation) (n= 1)
Discontinued intervention (medication) (n= 1)
Failed appointment (n = 1)
Allocated to Control Group (n= 20)
¨ Received allocated intervention (n= 20)
¨ Did not receive allocated intervention  (n= 0)
Analyzed (n=20)

































































































































































































































































































































































































































































































































































































































































































































































































































































































Have	you	had	difficulty	 doing	your	usual	 jobs	 because	of	problems with	your	teeth	or	
mouth?	
0.38










Table 3. Multivariate Linear Regression for Change in Irregularity and Average Daily 








































Dependent	Variables		 Independent	Variable		 B	 95%	Confidence	Interval	 p	 Sig	
	Irregularity	T0-T1	 Average	Daily	Compliance	T0-T1	 -0.343	 -1.642	–	0.956	 0.595	 NS	
	Irregularity	T1-T2	 Average	Daily	Compliance	T1-T2	 -0.508	 -1.949	–	0.932	 0.479	 NS	
	Irregularity	T2-T3	 Average	Daily	Compliance	T2-T3	 -0.297	 -1.060	–	0.465	 0.434	 NS	







Table 4. Pearson’s Correlation between Change in Irregularity and Change in Biomarker 












Variables	(T0-T1)	 Group	 R	 p	 Sig	
	Irregularity	and	TNFα	Concentration	 AcceledentÒ	 0.174	 0.463	 NS	
	Irregularity	and	TNFα	Concentration	 Control	 0.088	 0.721	 NS	
	Irregularity	and	IL6	Concentration	 AcceledentÒ	 -0.082	 0.730	 NS	
	Irregularity	and	IL6	Concentration	 Control	 -0161	 0.511	 NS	
	Irregularity	and	MMP9	Concentration	 AcceledentÒ	 -0.009	 0.971	 NS	
	Irregularity	and	MMP9	Concentration	 Control	 0.156	 0.523	 NS	
	Irregularity	and	IL3	Concentration	 AcceledentÒ	 0.079	 0.742	 NS	
	Irregularity	and	IL3	Concentration	 Control	 0.029	 0.906	 NS	
	Irregularity	and	IL8	Concentration	 AcceledentÒ	 0.079	 0.739	 NS	
	Irregularity	and	IL8	Concentration	 Control	 -0.024	 0.924	 NS	
	Irregularity	and	MMP1	Concentration	 AcceledentÒ	 0.075	 0.753	 NS	
	Irregularity	and	MMP1	Concentration	 Control	 0.136	 0.578	 NS	
	Irregularity	and	MMP8	Concentration	 AcceledentÒ	 -0.037	 0.878	 NS	
	Irregularity	and	MMP8	Concentration	 Control	 -0.048	 0.845	 NS	
	Irregularity	and	IL1β	Concentration	 AcceledentÒ	 0.012	 0.96	 NS	
	Irregularity	and	IL1β	Concentration	 Control	 0.028	 0.908	 NS	
	Irregularity	and	DKK1	Concentration	 AcceledentÒ	 0.105	 0.659	 NS	
	Irregularity	and	DKK1	Concentration	 Control	 0.016	 0.947	 NS	
	Irregularity	and	MMP13	Concentration	 AcceledentÒ	 0.297	 0.203	 NS	
	Irregularity	and	MMP13	Concentration	 Control	 0.149	 0.541	 NS	
	Irregularity	and	SOST	Concentration	 AcceledentÒ	 0.246	 0.296	 NS	
	Irregularity	and	SOST	Concentration	 Control	 0.137	 0.575	 NS	
	Irregularity	and	RANKL	Concentration	 AcceledentÒ	 0.019	 0.938	 NS	
	Irregularity	and	RANKL	Concentration	 Control	 0.052	 0.834	 NS	
	Irregularity	and	OPN	Concentration	 AcceledentÒ	 0.074	 0.756	 NS	
	Irregularity	and	OPN	Concentration	 Control	 0.189	 0.439	 NS	
	Irregularity	and	IL11	Concentration	 AcceledentÒ	 0.190	 0.422	 NS	
	Irregularity	and	IL11	Concentration	 Control	 0.164	 0.503	 NS	
	Irregularity	and	IL18	Concentration	 AcceledentÒ	 0.336	 0.147	 NS	
	Irregularity	and	IL18	Concentration	 Control	 0.118	 0.632	 NS	
	Irregularity	and	OPG	Concentration	 AcceledentÒ	 -0.145	 0.543	 NS	
	Irregularity	and	OPG	Concentration	 Control	 0.119	 0.627	 NS	
	Irregularity	and	TGFβ1	Concentration	 AcceledentÒ	 -0.037	 0.877	 NS	
	Irregularity	and	TGFβ1	Concentration	 Control	 0.011	 0.963	 NS	







Table 5. Pearson’s Correlation between Change in Irregularity and Change in Biomarker 














Variables	(T1-T2)	 Group	 R	 p	 Sig	
	Irregularity	and	TNFα	Concentration	 AcceledentÒ	 -0.118	 0.620	 NS	
	Irregularity	and	TNFα	Concentration	 Control	 -0.164	 0.515	 NS	
	Irregularity	and	IL6	Concentration	 AcceledentÒ	 -0.259 0.270 NS	
	Irregularity	and	IL6	Concentration	 Control	 0.051	 0.841	 NS	
	Irregularity	and	MMP9	Concentration	 AcceledentÒ	 -0.496	 0.026	 NS	
	Irregularity	and	MMP9	Concentration	 Control	 -0.219	 0.382	 NS	
	Irregularity	and	IL3	Concentration	 AcceledentÒ	 -0.268	 0.253	 NS	
	Irregularity	and	IL3	Concentration	 Control	 -0.149	 0.556	 NS	
	Irregularity	and	IL8	Concentration	 AcceledentÒ	 -0.481	 0.032	 NS	
	Irregularity	and	IL8	Concentration	 Control	 -0.332	 0.178	 NS	
	Irregularity	and	MMP1	Concentration	 AcceledentÒ	 -0.545	 0.013	 NS	
	Irregularity	and	MMP1	Concentration	 Control	 0.108	 0.669	 NS	
	Irregularity	and	MMP8	Concentration	 AcceledentÒ	 -0.509	 0.022	 NS	
	Irregularity	and	MMP8	Concentration	 Control	 -0.037	 0.885	 NS	
	Irregularity	and	IL1β	Concentration	 AcceledentÒ	 -0.485	 0.030	 NS	
	Irregularity	and	IL1β	Concentration	 Control	 -0.311	 0.210	 NS	
	Irregularity	and	DKK1	Concentration	 AcceledentÒ	 -0.421	 0.065	 NS	
	Irregularity	and	DKK1	Concentration	 Control	 -0.11	 0.663	 NS	
	Irregularity	and	MMP13	Concentration	 AcceledentÒ	 -0.025	 0.917	 NS	
	Irregularity	and	MMP13	Concentration	 Control	 0.268	 0.282	 NS	
	Irregularity	and	SOST	Concentration	 AcceledentÒ	 -0.126	 0.598	 NS	
	Irregularity	and	SOST	Concentration	 Control	 0.216	 0.390	 NS	
	Irregularity	and	RANKL	Concentration	 AcceledentÒ	 -0.341	 0.141	 NS	
	Irregularity	and	RANKL	Concentration	 Control	 -0.291	 0.242	 NS	
	Irregularity	and	OPN	Concentration	 AcceledentÒ	 -0.174	 0.463	 NS	
	Irregularity	and	OPN	Concentration	 Control	 -0.043	 0.865	 NS	
	Irregularity	and	IL11	Concentration	 AcceledentÒ	 -0.279	 0.233	 NS	
	Irregularity	and	IL11	Concentration	 Control	 0.140	 0.581	 NS	
	Irregularity	and	IL18	Concentration	 AcceledentÒ	 -0.505	 0.023	 NS	
	Irregularity	and	IL18	Concentration	 Control	 0.096	 0.704	 NS	
	Irregularity	and	OPG	Concentration	 AcceledentÒ	 -0.529	 0.016	 NS	
	Irregularity	and	OPG	Concentration	 Control	 -0.339	 0.169	 NS	
	Irregularity	and	TGFβ1	Concentration	 AcceledentÒ	 -0.515	 0.020	 NS	








Table 6. Pearson’s Correlation between Change in Irregularity and Change in Biomarker 














Variables	(T2-T3)	 Group	 R	 p	 Sig	
	Irregularity	and	TNFα	Concentration	 AcceledentÒ	 0.003	 0.991	 NS	
	Irregularity	and	TNFα	Concentration	 Control	 -0.231	 0.390	 NS	
	Irregularity	and	IL6	Concentration	 AcceledentÒ	 -0.023	 0.922	 NS	
	Irregularity	and	IL6	Concentration	 Control	 -0.053	 0.846	 NS	
	Irregularity	and	MMP9	Concentration	 AcceledentÒ	 -0.447	 0.048	 NS	
	Irregularity	and	MMP9	Concentration	 Control	 -0.550	 0.839	 NS	
	Irregularity	and	IL3	Concentration	 AcceledentÒ	 0.295	 0.206	 NS	
	Irregularity	and	IL3	Concentration	 Control	 -0.122	 0.652	 NS	
	Irregularity	and	IL8	Concentration	 AcceledentÒ	 -0.233	 0.322	 NS	
	Irregularity	and	IL8	Concentration	 Control	 -0.354	 0.179	 NS	
	Irregularity	and	MMP1	Concentration	 AcceledentÒ	 0.074	 0.756	 NS	
	Irregularity	and	MMP1	Concentration	 Control	 -0.162	 0.550	 NS	
	Irregularity	and	MMP8	Concentration	 AcceledentÒ	 -0.115	 0.630	 NS	
	Irregularity	and	MMP8	Concentration	 Control	 -0.242	 0.367	 NS	
	Irregularity	and	IL1β	Concentration	 AcceledentÒ	 -0.147	 0.535	 NS	
	Irregularity	and	IL1β	Concentration	 Control	 -0.155	 0.567	 NS	
	Irregularity	and	DKK1	Concentration	 AcceledentÒ	 0.239	 0.311	 NS	
	Irregularity	and	DKK1	Concentration	 Control	 -0.122	 0.654	 NS	
	Irregularity	and	MMP13	Concentration	 AcceledentÒ	 0.194	 0.413	 NS	
	Irregularity	and	MMP13	Concentration	 Control	 0.027	 0.921	 NS	
	Irregularity	and	SOST	Concentration	 AcceledentÒ	 0.292	 0.212	 NS	
	Irregularity	and	SOST	Concentration	 Control	 -0.426	 0.100	 NS	
	Irregularity	and	RANKL	Concentration	 AcceledentÒ	 0.234	 0.321	 NS	
	Irregularity	and	RANKL	Concentration	 Control	 -0.113	 0.678	 NS	
	Irregularity	and	OPN	Concentration	 AcceledentÒ	 0.015	 0.950	 NS	
	Irregularity	and	OPN	Concentration	 Control	 -0.268	 0.315	 NS	
	Irregularity	and	IL11	Concentration	 AcceledentÒ	 -0.059	 0.803	 NS	
	Irregularity	and	IL11	Concentration	 Control	 -0.162	 0.549	 NS	
	Irregularity	and	IL18	Concentration	 AcceledentÒ	 0.190	 0.422	 NS	
	Irregularity	and	IL18	Concentration	 Control	 -0.302	 0.256	 NS	
	Irregularity	and	OPG	Concentration	 AcceledentÒ	 -0.377	 0.146	 NS	
	Irregularity	and	OPG	Concentration	 Control	 -0.377	 0.150	 NS	
	Irregularity	and	TGFβ1	Concentration	 AcceledentÒ	 -0.298	 0.202	 NS	








Table 7. Pearson’s Correlation between Change in Irregularity and Change in Biomarker 




Variables	(T0-T3)	 Group	 R	 p	 Sig	
	Irregularity	and	TNFα	Concentration	 AcceledentÒ	 0.239	 0.311	 NS	
	Irregularity	and	TNFα	Concentration	 Control	 0.145	 0.592	 NS	
	Irregularity	and	IL6	Concentration	 AcceledentÒ	 0.112	 0.639	 NS	
	Irregularity	and	IL6	Concentration	 Control	 0.306	 0.249	 NS	
	Irregularity	and	MMP9	Concentration	 AcceledentÒ	 -0.280	 0.233	 NS	
	Irregularity	and	MMP9	Concentration	 Control	 0.550	 0.027	 NS	
	Irregularity	and	IL3	Concentration	 AcceledentÒ	 0.274	 0.242	 NS	
	Irregularity	and	IL3	Concentration	 Control	 -0.095	 0.727	 NS	
	Irregularity	and	IL8	Concentration	 AcceledentÒ	 -0.164	 0.489	 NS	
	Irregularity	and	IL8	Concentration	 Control	 0.212	 0.431	 NS	
	Irregularity	and	MMP1	Concentration	 AcceledentÒ	 0.089	 0.708	 NS	
	Irregularity	and	MMP1	Concentration	 Control	 0.406	 0.118	 NS	
	Irregularity	and	MMP8	Concentration	 AcceledentÒ	 0.132	 0.578	 NS	
	Irregularity	and	MMP8	Concentration	 Control	 0.388	 0.137	 NS	
	Irregularity	and	IL1β	Concentration	 AcceledentÒ	 0.250	 0.289	 NS	
	Irregularity	and	IL1β	Concentration	 Control	 0.122	 0.652	 NS	
	Irregularity	and	DKK1	Concentration	 AcceledentÒ	 0.132	 0.578	 NS	
	Irregularity	and	DKK1	Concentration	 Control	 -0.54	 0.842	 NS	
	Irregularity	and	MMP13	Concentration	 AcceledentÒ	 0.299	 0.201	 NS	
	Irregularity	and	MMP13	Concentration	 Control	 0.139	 0.609	 NS	
	Irregularity	and	SOST	Concentration	 AcceledentÒ	 0.218	 0.355	 NS	
	Irregularity	and	SOST	Concentration	 Control	 0.114	 0.675	 NS	
	Irregularity	and	RANKL	Concentration	 AcceledentÒ	 0.498	 0.025	 NS	
	Irregularity	and	RANKL	Concentration	 Control	 0.233	 0.386	 NS	
	Irregularity	and	OPN	Concentration	 AcceledentÒ	 0.219	 0.353	 NS	
	Irregularity	and	OPN	Concentration	 Control	 0.024	 0.930	 NS	
	Irregularity	and	IL11	Concentration	 AcceledentÒ	 0.273	 0.243	 NS	
	Irregularity	and	IL11	Concentration	 Control	 0.201	 0.456	 NS	
	Irregularity	and	IL18	Concentration	 AcceledentÒ	 0.189	 0.424	 NS	
	Irregularity	and	IL18	Concentration	 Control	 -0.101	 0.709	 NS	
	Irregularity	and	OPG	Concentration	 AcceledentÒ	 -0.174	 0.462	 NS	
	Irregularity	and	OPG	Concentration	 Control	 0.385	 0.141	 NS	
	Irregularity	and	TGFβ1	Concentration	 AcceledentÒ	 -0.360	 0.119	 NS	
	Irregularity	and	TGFβ1	Concentration	 Control	 0.086	 0.751	 NS	
	
